Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects

NCT07055412 | Not Yet Recruiting Phase 1

• 1 other identifier: Y-3-LC-07
• Study Type: interventional
• Target: 24
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to assess the pharmacokinetic profiles and safety of Y-3 in subjects with mild hepatic insufficiency (Child-Pugh: grade A), moderate hepatic insufficiency (Child-Pugh: grade B) and gender, age, and weight matching normal hepatic function, so as to provide a scientific basis for rational clinical medication in patients with hepatic insufficiency. The main questions it aims to answer are: What the pharmacokinetic profiles of Y-3 (40 mg ) in subjects with mild hepatic insufficiency (Child-Pugh: grade A), moderate hepatic insufficiency (Child-Pugh: grade B) and gender, age, and weight matching normal hepatic function？ If drug Y-3 (40mg ) is safe and tolerate in subjects with mild hepatic insufficiency (Child-Pugh: grade A), moderate hepatic insufficiency (Child-Pugh: grade B) and gender, age, and weight matching normal hepatic function. Investigators will compare pharmacokinetic safety profiles of Y-3 (40 mg ) in subjects with different hepatic functions( mild hepatic insufficiency, moderate hepatic insufficiency, normal. Participants will: Take drug Y-3 (40 mg) only once. Answer questions regarding your medical history. Comply with the study procedures and requests. Complete all tests and collections of PK Sampling. Fasting for more than 10 hours before administration, water abstinence for 1 h before and after administration, and eating standard lunch and dinner 4 hours and 10 hours after starting administration. Must not use of nicotine-containing products (including nicotine patches). Must not do strenuous exercise for 1 hour before each clinical laboratory test blood draw. Subjects may engage in light recreational activities for the duration of the study. Follow your doctor's instructions, answer the investigator's questions about your health status truthfully, and cooperate with the test-related tests. During the experiment, the test should be completed in strict accordance with the requirements of the investigator, and the test-related work such as drug administration and sample collection should be conscientiously cooperated, and the research center should not leave the research center without authorization, and the rules and regulations of the research center and the investigator 's propaganda and education should be observed. Any medication taken should be reported truthfully. Must come to the hospital at the agreed follow-up time with the investigator and you. Inform the investigator or relevant person about any changes in your health status, including any favorable or unfavorable changes. Must not participate in any other drug clinical trials during this trial. Must tell your investigator about all medical treatments you plan to receive during the study, such as elective surgery or radiation therapy. In addition to yourself, at least one member of your family is expected to be aware of the clinical research you will be involved in and care about your health, and will be able to provide feedback to your doctor about your health during follow-up visits. Your family should promptly notify your study physician if you become seriously unwell, including hospitalization for treatment. Notify your investigator if your address, phone number, or other contact information changes. Must not use medications that may interfere with PK or safety.

Conditions

Pharmacokinetic Differences; Y-3; Saftey; Mild Hepatic Insufficiency; Moderate Hepatic Insufficiency; Normal Hepatic Function

Outcome Measures

Primary Outcomes (3)

• Evaluate the Cmax of Y-3 (40 mg ) in subjects with mild hepatic insufficiency , moderate hepatic insufficiency and gender, age, and weight matching normal hepatic function by venous blood and Phoenix WinNonlin

  Maximum observed plasma concentration. It was obtained directly from the measured plasma concentration-time data.

  single-dose administration period (Day1-Day6)

• Evaluate the AUC 0-t of of Y-3 (40 mg ) in subjects with mild hepatic insufficiency , moderate hepatic insufficiency and gender, age, and weight matching normal hepatic function by venous blood and Phoenix WinNonlin.

  Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration. Calculated according to linearity trapezoidal rule: AUC (i, i+1) = (Ti+1-Ti) (Ci+Ci+1) /2, and AUC0-t is the sum of all AUC (i, i + 1).

  single-dose administration period (Day1-Day6)

• Evaluate the AUC 0-∞ of Y-3 (40 mg) in subjects with mild hepatic insufficiency , moderate hepatic insufficiency and gender, age, and weight matching normal hepatic function by venous blood and Phoenix WinNonlin.

  Area under the concentration-time curve from time 0 to infinity (extrapolated). AUC 0-∞ =AUC 0-t + Ct/λz (Ct is the last measured plasma concentration).

  single-dose administration period (Day1-Day6)

Secondary Outcomes (16)

• Evaluate the Tmax of Y-3 (40 mg ) in subjects with mild hepatic insufficiency , moderate hepatic insufficiency and gender, age, and weight matching normal hepatic function by venous blood and Phoenix WinNonlin.

  single-dose administration period (Day1-Day6)

• Evaluate the t1/2 of Y-3 (40 mg ) in subjects with mild hepatic insufficiency, moderate hepatic insufficiency and gender, age, and weight matching normal hepatic function by venous blood and Phoenix WinNonlin.

  single-dose administration period (Day1-Day6)

• Evaluate the λz of Y-3 (40 mg ) in subjects with mild hepatic insufficiency, moderate hepatic insufficiency and gender, age, and weight matching normal hepatic function by venous blood and Phoenix WinNonlin.

  single-dose administration period (Day1-Day6)

• Evaluate the AUC_%Extrap of Y-3 (40 mg ) in subjects with mild hepatic insufficiency, moderate hepatic insufficiency and gender, age, and weight matching normal hepatic function by venous blood and Phoenix WinNonlin.

  single-dose administration period (Day1-Day6)

• Evaluate the Vz of Y-3 (40 mg) in subjects with mild hepatic insufficiency, moderate hepatic insufficiency and gender, age, and weight matching normal hepatic function by venous blood and Phoenix WinNonlin.

  single-dose administration period (Day1-Day6)

Study Arms (1)

Y-3（40mg）

EXPERIMENTAL

Drug: Y-3 for injection（40mg）

Interventions

Y-3 for injection（40mg） DRUG

The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution). Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd.

Y-3（40mg）

Eligibility Criteria

• Age: 18 Years - 70 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The subject fully understands the purpose and requirements of this trial, voluntarily participates in the clinical trial and signs a written ICF, strictly abide by the clinical study protocols and requirements to complete the whole study process;
• Be 18\~70 years old (including the boundary value) on the day of signing the ICF, both male and female;
• At screening, the weight of male subjects ≥ 50kg, the weight of female subjects ≥ 45kg, and the body mass index \[BMI=Weight (kg)/height 2 (m2)\] within the range of 18.0\~30.0kg/m2 (including boundary value);
• Subjects (including their spouses or partners) have no sperm or egg donation programs, no fertility plans, and voluntary strict contraceptive use during the trial and within 3 months after the completion of the trial, see Appendix 1: Contraceptive measures administration and contraceptive requirements;
• The estimated glomerular filtration rate (eGFR) calculated using the modification of diet in renal disease (MDRD) formula ≥ 80 ml/min/1.73 m2. (See Appendix 2: Glomerular Filtration Rate Calculation Formula);
• Subjects with hepatic insufficiency must also meet all of the following criteria:
• Chronic liver injury caused by primary liver disease (such as hepatitis B, hepatitis C, autoimmune hepatitis, alcoholic liver disease, non-alcoholic liver disease, fatty liver, etc.) or clinical diagnosis of liver cirrhosis (see Appendix 3: Diagnostic Criteria for Liver Cirrhosis) caused by primary liver disease, Child-Pugh grade A or B patients with hepatic insufficiency (see Appendix 4: Liver Function Assessment for Child-Pugh classification), and have not used albumin within 14 days before screening, and the investigator judged that patients with mild hepatic insufficiency need to be clinically stable ≥for 28 days before taking the investigational products, and patients with moderate hepatic insufficiency need to be clinically ≥stable for 14 days before taking the investigational products, and the investigator judges that the subject's liver function status is stable from 2 weeks before screening to the end of the study, and no obvious deterioration will occur;
• Have not taken any medication within 1 week before screening; or those who require long-term treatment for liver damage, complications and/or other concomitant diseases should have stable medication for at least 4 weeks (stable medication is judged by the investigator, except for drugs prohibited by the protocol).
• Subjects with normal liver function also need to meet all of the following criteria:
• The demographic mean of subjects in the normal hepatic function group (Group C) at screening must meet the following matching standard:
• Sex matching with liver insufficiency group (group A and group B), with a mean value of ±1 case;
• Age matching with hepatic insufficiency group (Group A and Group B) with a mean ± 10 years;
• Body weight matching with hepatic insufficiency group (group A and group B) with a mean of ±10%.

You may not qualify if:

• Irritable the physique, such as those with a known history of allergy to two or more substances, or those with allergic diseases, or those with a history of allergy to investigational products or excipients (15-hydroxystearate polyethylene glycol, propylene glycol, potassium dibasic phosphate, potassium dibasic phosphate trihydrate, mannitol);
• Those who have special dietary requirements and cannot comply with the uniform diet;
• Patients with clinically significant ECG abnormalities (tachycardia/bradycardia, II-III degree atrioventricular block or QTcF interval prolongation (QTcF\>450ms for males and \>470ms for females) (corrected according to Fridericia's formula: QTcF=QT/(RR\^0.33), RR=60/heart rate) or other clinically significant abnormalities judged by the investigator to be unsuitable for participating in this study);
• Those who have serious infection, trauma, gastrointestinal surgery or other surgical procedures within 4 weeks before screening, or those who plan to undergo surgical treatment during the trial or have a tendency to be hospitalized;
• Those who have lost blood or donated ≥ 400 mL of blood within 3 months before dosing, or who have received blood transfusion or used blood products within 1 month, or who plan to donate blood within 1 month after the end of this trial;
• Those who have used medium or strong inhibitors or inducers of CYP450 enzyme within 1 month before dosing (such as phenytoin, rifampicin, carbamazepine, fluvoxamine, enoxacin, ticlopidine, gemfibrozil, clopidogrel, clarithromycin, itraconazole, ketoconazole, ritonavir, etc., see Appendix 5: List of Common Drugs for CYP Enzyme Inhibitors or Inducers) or UGT enzyme inhibitors or inducers (such as atazanavir, probenecid, valpendict, mefenamic acid, carbamazepine, rifampicin) within 1 month before dosing , phenytoin, efaviren, phenobarbital, ritonavir, etc., see Appendix 6: List of common drugs for UGT enzyme inhibitors or inducers);
• Those who have consumed excessive amounts of tea, coffee and/or caffeinated beverages per day (an average of more than 8 cups per day, 1 cup = 250mL) within 3 months before screening, and those who cannot withdraw during the trial; or those who have consumed a special diet (including dragon fruit, mango, grapefruit, xanthine-rich food, chocolate, etc.) within 2 weeks before screening;
• Those who have participated in other clinical trials and received investigational products within 3 months before screening, or those who plan to participate in other clinical trials during this study;
• Those who are current or previous alcoholics or regular drinkers within 6 months prior to screening, that is, those who drink more than 14 units of alcohol per week (1 unit = 360mL of beer or 45mL of spirits with 40% alcohol or 150mL of wine), or those who have a positive alcohol breath test at baseline (alcohol breath test result \>0 mg/100 mL) or those who cannot withdraw during the trial;
• Those with a history of drug abuse or drug use or a positive urine drug screen;
• Those who are cigarette-addict or smoking more than 5 cigarettes per day within 3 months prior to screening or habitual use of nicotine-containing system and are unable to withdraw during the test;
• Those who have received vaccination within 30 days before screening, or plan to be vaccinated during the study;
• Pregnant or lactating women, or women of childbearing age who have a positive blood pregnancy test;
• Patients who have difficulty in venous blood collection and cannot tolerate venipuncture or fainting needles and blood;
• Subjects with poor compliance in the opinion of the investigators, or with other factors that are not suitable for participating in this trial.

Sponsors & Collaborators

• Neurodawn Pharmaceutical Co., Ltd.: lead

Central Study Contacts

Shuang Li

CONTACT

13938529645; li36918@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 20, 2025
• First Posted: July 8, 2025
• Study Start: July 10, 2025
• Primary Completion: October 31, 2025
• Study Completion: December 31, 2025
• Last Updated: July 8, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share